Tiziana Life Sciences Highlighted in Forbes Article

March 17, 2023

https://www.globenewswire.com/news-release/2023/03/17/2629396/0/en/Tiziana-Life-Sciences-Highlighted-in-Forbes-Article.html

NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq:TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company was highlighted in a FORBES article highlighting foralumab, the Company’s unique intranasal monoclonal antibody, which is currently in clinical development to treat multiple sclerosis and a range of other neurodegenerative diseases. Foralumab is the world’s only fully human, anti-CD3 mAb in clinical development.

Read more at globenewswire.com

Related news for (TLSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.